GioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1 Results published today in F…
Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
GioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1 Results published today in F…